Table IV.
Univariate analysis of clinicopathological parameters for overall and progression-free survival in patients with breast ductal carcinoma with a co-negative and co-positive p-Smad2/Smad4 expression.
| Overall survival time (months) | Progress-free survival time (months) | ||||
|---|---|---|---|---|---|
| Variable | Cases | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (year) | 120 | 0.516 | 0.999 | ||
| <48 | 59 | 1 | 1 | ||
| ≥48 | 61 | 0.793 (0.395–1.596) | 1 (0.592–1.689) | ||
| Histological grade | 0.084 | 0.284 | |||
| I | 16 | 1 | 1 | ||
| II | 76 | 2.163 (0.504–9.287) | 1.047 (0.463–2.367) | ||
| III | 28 | 4.186 (0.927–18.904) | 1.660 (0.682–4.038) | ||
| Tumor size | 0.158 | 0.447 | |||
| T2 | 94 | 1 | 1 | ||
| T3 | 26 | 1.744 (0.806–3.772) | 1.272 (0.684–2.367) | ||
| Lymph node metastasis | 0.917 | 0.683 | |||
| N0 | 40 | 1 | 1 | ||
| N1 | 36 | 0.806 (0.324–2.005) | 1.215 (0.637–2.316) | ||
| N2 | 23 | 0.998 (0.387–2.575) | 0.781 (0.351–1.740) | ||
| N3 | 21 | 1.176 (0.435–3.181) | 1.243 (0.573–2.694) | ||
| Distant metastasis | 0.022a | 0.012a | |||
| M0 | 112 | 1 | 1 | ||
| M1 | 8 | 3.412 (1.190–9.777) | 2.986 (1.274–6.998) | ||
| ER | 0.770 | 0.919 | |||
| Negative | 89 | 1 | 1 | ||
| Positive | 31 | 1.122 (0.519–2.425) | 0.969 (0.529–1.774) | ||
| PR | 0.463 | 0.675 | |||
| Negative | 85 | 1 | 1 | ||
| Positive | 35 | 0.741 (0.333–1.650) | 1.127 (0.643–1.976) | ||
| HER2 | 0.125 | 0.796 | |||
| Negative | 89 | 1 | 1 | ||
| Positive | 31 | 1.751 (0.856–3.583) | 1.081 (0.598–1.954) | ||
| Smad2 | 0.750 | 0.543 | |||
| Low | 59 | 1 | 1 | ||
| High | 61 | 0.893 (0.446–1.788) | 1.178 (0.695–1.995) | ||
| p-Smad2 and Smad4 | 0.047a | 0.023a | |||
| p-Smad2/Smad4 co-negative | 20 | 1 | 1 | ||
| p-Smad2/Smad4 co-positive | 100 | 0.458 (0.212–0.991) | 0.486 (0.261–0.905) | ||
a
P<0.05. Smad, SMAD family member; p-, phosphorylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval.